Literature DB >> 35944066

Functional and biological heterogeneity of KRASQ61 mutations.

Minh V Huynh1, G Aaron Hobbs2, Antje Schaefer3,4, Mariaelena Pierobon5, Leiah M Carey1,4, J Nathaniel Diehl6, Jonathan M DeLiberty3, Ryan D Thurman1, Adelaide R Cooke4, Craig M Goodwin4, Joshua H Cook7,8,9, Lin Lin10, Andrew M Waters3,4, Naim U Rashid11, Emanuel F Petricoin5, Sharon L Campbell1,4, Kevin M Haigis7,8,12,13, Diane M Simeone14, Costas A Lyssiotis10,15,16, Adrienne D Cox3,4,17, Channing J Der3,4,6.   

Abstract

Missense mutations at the three hotspots in the guanosine triphosphatase (GTPase) RAS-Gly12, Gly13, and Gln61 (commonly known as G12, G13, and Q61, respectively)-occur differentially among the three RAS isoforms. Q61 mutations in KRAS are infrequent and differ markedly in occurrence. Q61H is the predominant mutant (at 57%), followed by Q61R/L/K (collectively 40%), and Q61P and Q61E are the rarest (2 and 1%, respectively). Probability analysis suggested that mutational susceptibility to different DNA base changes cannot account for this distribution. Therefore, we investigated whether these frequencies might be explained by differences in the biochemical, structural, and biological properties of KRASQ61 mutants. Expression of KRASQ61 mutants in NIH 3T3 fibroblasts and RIE-1 epithelial cells caused various alterations in morphology, growth transformation, effector signaling, and metabolism. The relatively rare KRASQ61E mutant stimulated actin stress fiber formation, a phenotype distinct from that of KRASQ61H/R/L/P, which disrupted actin cytoskeletal organization. The crystal structure of KRASQ61E was unexpectedly similar to that of wild-type KRAS, a potential basis for its weak oncogenicity. KRASQ61H/L/R-mutant pancreatic ductal adenocarcinoma (PDAC) cell lines exhibited KRAS-dependent growth and, as observed with KRASG12-mutant PDAC, were susceptible to concurrent inhibition of ERK-MAPK signaling and of autophagy. Our results uncover phenotypic heterogeneity among KRASQ61 mutants and support the potential utility of therapeutic strategies that target KRASQ61 mutant-specific signaling and cellular output.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35944066      PMCID: PMC9534304          DOI: 10.1126/scisignal.abn2694

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   9.517


  66 in total

Review 1.  KRAS Alleles: The Devil Is in the Detail.

Authors:  Kevin M Haigis
Journal:  Trends Cancer       Date:  2017-09-12

2.  Integrated RAS signaling defined by parallel NMR detection of effectors and regulators.

Authors:  Matthew J Smith; Mitsuhiko Ikura
Journal:  Nat Chem Biol       Date:  2014-01-19       Impact factor: 15.040

3.  Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Authors:  Christin E Burd; Wenjin Liu; Minh V Huynh; Meriam A Waqas; James E Gillahan; Kelly S Clark; Kailing Fu; Brit L Martin; William R Jeck; George P Souroullas; David B Darr; Daniel C Zedek; Michael J Miley; Bruce C Baguley; Sharon L Campbell; Norman E Sharpless
Journal:  Cancer Discov       Date:  2014-09-24       Impact factor: 39.397

4.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

5.  Structural insight into the rearrangement of the switch I region in GTP-bound G12A K-Ras.

Authors:  Shenyuan Xu; Brian N Long; Gabriel H Boris; Anqi Chen; Shuisong Ni; Michael A Kennedy
Journal:  Acta Crystallogr D Struct Biol       Date:  2017-11-10       Impact factor: 7.652

6.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Authors:  Kirsten L Bryant; Clint A Stalnecker; Daniel Zeitouni; Jennifer E Klomp; Sen Peng; Andrey P Tikunov; Venugopal Gunda; Mariaelena Pierobon; Andrew M Waters; Samuel D George; Garima Tomar; Björn Papke; G Aaron Hobbs; Liang Yan; Tikvah K Hayes; J Nathaniel Diehl; Gennifer D Goode; Nina V Chaika; Yingxue Wang; Guo-Fang Zhang; Agnieszka K Witkiewicz; Erik S Knudsen; Emanuel F Petricoin; Pankaj K Singh; Jeffrey M Macdonald; Nhan L Tran; Costas A Lyssiotis; Haoqiang Ying; Alec C Kimmelman; Adrienne D Cox; Channing J Der
Journal:  Nat Med       Date:  2019-03-04       Impact factor: 53.440

7.  Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.

Authors:  G Aaron Hobbs; Nicole M Baker; Anne M Miermont; Ryan D Thurman; Mariaelena Pierobon; Timothy H Tran; Andrew O Anderson; Andrew M Waters; J Nathaniel Diehl; Bjoern Papke; Richard G Hodge; Jennifer E Klomp; Craig M Goodwin; Jonathan M DeLiberty; Junning Wang; Raymond W S Ng; Prson Gautam; Kirsten L Bryant; Dominic Esposito; Sharon L Campbell; Emanuel F Petricoin; Dhirendra K Simanshu; Andrew J Aguirre; Brian M Wolpin; Krister Wennerberg; Udo Rudloff; Adrienne D Cox; Channing J Der
Journal:  Cancer Discov       Date:  2019-10-24       Impact factor: 38.272

8.  Microinjection of recombinant p21rho induces rapid changes in cell morphology.

Authors:  H F Paterson; A J Self; M D Garrett; I Just; K Aktories; A Hall
Journal:  J Cell Biol       Date:  1990-09       Impact factor: 10.539

9.  NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy.

Authors:  Woonghee Lee; Marco Tonelli; John L Markley
Journal:  Bioinformatics       Date:  2014-12-12       Impact factor: 6.937

10.  Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth.

Authors:  Sarbajeet Nagdas; Jennifer A Kashatus; Aldo Nascimento; Syed S Hussain; Riley E Trainor; Sarah R Pollock; Sara J Adair; Alex D Michaels; Hiromi Sesaki; Edward B Stelow; Todd W Bauer; David F Kashatus
Journal:  Cell Rep       Date:  2019-08-13       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.